


Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

4

Application Number

09/642,660

Filing Date

August 22, 2000

First Named Inventor

Jonathan Schneck et al.

Group Art Unit

1642

Examiner Name

G. Bansal

TECH
CENTER

JAN 14 2002

Attorney Docket Number

01107.00042

RECEIVED

ENCLOSURES (check all that apply)

- | | | |
|--|---|---|
| <input checked="" type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input checked="" type="checkbox"/> Amendment / Response | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input type="checkbox"/> Other Enclosure(s)
(please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/ Incomplete Application | | Remarks |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Lisa M. Hemmendinger, Registration No. 42,653
Signature	
Date	January 10, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name		Date
Signature		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



#7B
1/20/02
TGray
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Schneck and O'Herrin) Group Art Unit: 1642
Serial No. 09/642,660) Examiner: G. Bansal
Filed: August 22, 2000)
) Atty. Docket No. 01107.00042

FOR: MOLECULAR COMPLEXES WHICH MODIFY IMMUNE RESPONSES

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Assistant Director of Patents
Washington, D.C. 20231

Sir:

This paper is filed in response to the Office Action mailed December 11, 2001. We believe no fee is due to make this amendment timely filed. If a fee is due, please charge Deposit Account No. 19-0733.

In response to the restriction requirement, Applicants elect Group III, claims 28-32. In addition, please enter the following amendments to the claims.

IN THE CLAIMS

Please cancel claims 1-27 and 33-50 and substitute the following new claims.

51. (New) The composition of claim 28 wherein the immunoglobulin heavy chain is an IgG1 heavy chain.

52. (New) The composition of claim 28 wherein the immunoglobulin light chain is an Igκ chain.

53. (New) The composition of claim 28 wherein the first fusion proteins comprise

JAN 14 2002
TECH CENTER 1600/2900

RECEIVED